Two Drug Combination Doubled Kidney Cancer Progression Free Survival

Two Drug Combination Doubled Kidney Cancer Progression Free Survival

Audio Journal of Oncology Podcast
Audio Journal of Oncology Podcast
Two Drug Combination Doubled Kidney Cancer Progression Free Survival
Loading
/

MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a combination of the vascular endothelial growth factor (VEGF) inhibitor axitinib plus the anti-programmed death one ligand (PD-L1) avelumab in comparison with those receiving standard sunitinib anti-VEGF therapy in the randomized phase threeJAVELIN Renal 101 clinical trial. Findings were reported at the 2018 annual congress of the European Society for Medical Oncology (ESMO).  http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=LBA6_PR

Robust PFS

“The progression free survival was so robust, the objective response rate was robust [and] the safety profile was favorable that [this] warrants this combination as a new standard of care in patients with advanced kidney cancer,”  lead investigator of the study Robert J Motzer MD PhD, a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York told the Audio Journal of Oncology.

Further reading

Sign up for AudioMedica.com news

* = required field
Speciality